VERU: Veru Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 88.42
Enterprise Value ($M) 68.40
Book Value ($M) 21.05
Book Value / Share 0.14
Price / Book 4.20
NCAV ($M) 9.75
NCAV / Share 0.07
Price / NCAV 9.07

Profitability (mra)
Return on Invested Capital (ROIC) -1.49
Return on Assets (ROA) -0.51
Return on Equity (ROE) -0.80

Liquidity (mrq)
Quick Ratio 3.80
Current Ratio 3.80

Balance Sheet (mrq) ($M)
Current Assets 21.38
Assets 32.67
Liabilities 11.62
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 16.89
Operating Income -38.14
Net Income -37.80
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -21.68
Cash from Investing 0.15
Cash from Financing 36.83

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-12 13G/A Adage Capital Partners Gp, L.l.c. 1.57 -83.24
11-12 13G/A Adage Capital Management, L.P. 5.37
11-08 13G BlackRock, Inc. 5.60 0.00
11-04 13G/A Millennium Management Llc 4.00 -22.99

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2025-02-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-12-16 10-K UNITED STATES ‎SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-06-05 383,611 1,568,395 24.46
2025-06-04 630,562 2,855,999 22.08
2025-06-03 370,896 3,119,396 11.89
2025-06-02 778,112 4,107,591 18.94

(click for more detail)

Similar Companies
UNCY – Unicycive Therapeutics, Inc. UPC – Universe Pharmaceuticals INC
UPXI – Upexi, Inc. VIVS – VivoSim Labs, Inc.
VKTX – Viking Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io